Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imidapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 13/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imidapril SCHEMBL22492310 | 1.00 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL6516062 | 1.00 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL683273 | 1.00 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL3193644 | 1.00 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL7354516 | 1.00 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL11014327 | 1.00 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL34099 | 1.00 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL12894585 | 1.00 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL7294155 | 0.99 | ACE (0.98) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL136722 | 0.99 | ACE (0.98) | ACELMNAABCB11MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10750 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | claimed |
| US-20250345332-A1 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-13 | — | — | US | claimed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | claimed |
| US-20250281447-A1 | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY | ANAVEX LIFE SCIENCES CORP. | 2025-09-11 | — | — | US | claimed |
| EP-4611904-A1 | COMPOSITIONS AND METHODS FOR TREATING NF1 AND OTHER CONDITIONS | Liby, Karen (US) | 2025-09-10 | — | — | EP | claimed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | claimed |
| EP-4595974-A2 | THERAPEUTIC COMBINATIONS OF TDFRPS AND ADDITIONAL AGENTS AND METHODS OF USE | Carlson, William D. (US) | 2025-08-06 | — | — | EP | claimed |
| EP-4580674-A2 | ANTIGEN BINDING MOLECULES TARGETING PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) | Flagship Pioneering Innovations VI, LLC (US) | 2025-07-09 | — | — | EP | claimed |
| CN-120044159-A | Polygonatum sibiricum medicinal material species identification method based on polygonatum sibiricum characteristic compound and application | 河北北方学院 | 2025-05-27 | — | — | CN | claimed |
| US-5160744-A | Sustained release by coating drug in polyoxyethylene glycol and another polymer that swells and expands and pushes the drug out | ALZA CORPORATION (US) | 1992-11-03 | — | — | US | claimed |
| EP-0272849-B1 | USE OF 2-OXO-IMIDAZOLIDINE DERIVATIVES IN THE TREATMENT OF KIDNEY DISEASES | Tanabe Seiyaku Co., Ltd. (JP) | 1992-10-14 | — | — | EP | claimed |
| EP-0274230-B1 | USE OF 2-OXO-IMIDAZOLIDINE DERIVATIVES IN THE PROPHYLAXIS AND TREATMENT OF HEART FAILURE | TANABE SEIYAKU CO., LTD. (JP) | 1992-10-14 | — | — | EP | claimed |
| EP-0488059-A2 | Use of a combination of an ace inhibitor with a calcium antagonist in the treatment of proteinuria | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-06-03 | — | — | EP | claimed |
| WO-1991015196-A1 | OSMOTIC DOSAGE SYSTEM FOR LIQUID DRUG DELIVERY | ALZA CORPORATION (US) | 1991-10-17 | — | — | WO | claimed |
| US-4888339-A | CARDIOTONIC AGENTS; 2-OXOIMIDAZOLIDINE | TANABE SEIYAKU CO., LTD. (JP) | 1989-12-19 | — | — | US | claimed |
| US-4804672-A | UROGENITIAL DISORDERS | TANABE SEIYAKU CO., LTD. (JP) | 1989-02-14 | — | — | US | claimed |
| EP-0274230-A2 | Use of 2-oxo-imidazolidine derivatives in the prophylaxis and treatment of heart failure | TANABE SEIYAKU CO., LTD. (JP) | 1988-07-13 | — | — | EP | claimed |
| EP-0272849-A2 | Use of 2-oxo-imidazolidine derivatives in the treatment of kidney diseases | Tanabe Seiyaku Co., Ltd. (JP) | 1988-06-29 | — | — | EP | claimed |
| US-4508727-A | Antihypertensive 2-oxo-imidazolidine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1985-04-02 | — | — | US | claimed |